Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-B455 in Advanced or Metastatic Solid Tumors
NCT06803680Phase 1Recruiting
- Sponsor
- BeOne Medicines
- Start
- Mar 2025
- Primary completion
- Apr 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of BGB-B455 in solid tumor (2 arms), sponsored by BeOne Medicines. Primary endpoints: Number of participants with adverse events and serious adverse events at 7 months, Maximum Tolerated Dose or Maximum Administered Dose at 1 month and 2 more. Started Mar 2025; status: recruiting.
02
Drugs
BGB-B455
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06803680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06803680.